| TWSE Exchange | United Kingdom Country |
Kanabo Group Plc is a pioneering digital health company founded in 2016 and headquartered in London, United Kingdom. The company is at the forefront of researching, developing, and commercializing innovative cannabis-derived formulations alongside therapeutic inhalation devices. Operating across Primary Care and Secondary Care segments, Kanabo aims to revolutionize the healthcare industry through its advanced technologies and comprehensive telehealth services. By focusing on the medicinal potential of cannabis, Kanabo Group Plc provides effective solutions for both patients and cannabis businesses, contributing to the growing recognition of cannabis's therapeutic benefits.
This online telehealth platform empowers patients by offering video consultations, online prescriptions, and a wide range of primary care services. By leveraging digital technology, The GP Service makes healthcare more accessible and efficient, reducing the need for in-person visits and providing a seamless experience for patients seeking medical care.
Focused on the management of chronic pain, Treat It serves as an online clinic providing specialized care for patients dealing with long-term pain conditions. This platform underscores Kanabo's commitment to addressing the often complex needs of individuals suffering from chronic pain, offering them tailored treatments and support.
Kanabo extends its expertise to the burgeoning cannabis industry through cultivation consultancy services. This offering is designed to assist cannabis businesses in optimizing their cultivation practices, ensuring quality control, and navigating the regulatory landscape, thereby promoting a sustainable and ethical cannabis market.
At the heart of Kanabo's product line are its cannabis-derived medicinal and wellness products. Developed through rigorous research and innovation, these products aim to provide effective and safe therapeutic options for a variety of conditions. With a focus on quality and efficacy, Kanabo is dedicated to enhancing patient well-being and advancing the therapeutic applications of cannabis.